Literature DB >> 32840688

Mid-term results of total hip arthroplasty for relapsed osteoarthritis after joint-preserving operations for coxarthritis compared to primary total hip arthroplasty.

Suguru Ohsawa1,2, Syuji Koide3, Takaaki Shibuya4.   

Abstract

PURPOSES: Several studies have reported no differences in outcomes between total hip arthroplasty (THA) of osteotomized hips and primary hip THA. However, our results were worse after THA for converted osteotomized hips. Therefore, this study's aim was to clarify the differences between THA after osteotomy and primary THA for osteoarthritis in developmental dysplasia of the hip (DDH).
METHODS: The data were collected retrospectively (December 1998-June 2013). The cohort contained patients with a previous osteotomy (40 femur osteotomies) for osteoarthritis with DDH who then underwent cementless THA (average 192 months after osteotomy). The clinical and radiographic outcomes of 40 hips (osteotomy group) were compared with a matched group of 40 hips after primary THA (primary group). THA was performed and investigated only in patients with DDH.
RESULTS: The mean follow-up period of the osteotomy group was 133 months. One patient was lost to follow-up. They had significantly higher subluxation and a narrower canal than the primary group (p < 0.0001, 0.017, respectively). Preoperative and final Harris Hip Score values were worse in the osteotomy group than in the primary group (preoperative 35 vs. 44, p = 0.0009; final 88 vs. 96, p = 0.0001, respectively). Manual muscle strengths of the hip flexor at final follow-up were worse in the osteotomy group. Radiographic outcomes of the osteotomy group showed a larger postoperative leg length discrepancy and severe periprosthetic bone atrophy as judged by bone mineral density and stress shielding.
CONCLUSION: Proximal femoral osteotomies showed worse outcomes after conversion THA at mid-term follow-up.

Entities:  

Keywords:  Hip; Osteoarthritis; Osteotomy; Total hip arthroplasty

Year:  2020        PMID: 32840688     DOI: 10.1007/s00590-020-02768-2

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  8 in total

1.  Results of a tapered cementless femoral stem implanted in varus.

Authors:  Cyna Khalily; D Kevin Lester
Journal:  J Arthroplasty       Date:  2002-06       Impact factor: 4.757

2.  Evaluation of periprosthetic bone using dual-energy x-ray absorptiometry: precision of the method and effect of operation on bone mineral density.

Authors:  H Kröger; H Miettinen; I Arnala; E Koski; N Rushton; O Suomalainen
Journal:  J Bone Miner Res       Date:  1996-10       Impact factor: 6.741

3.  [Total hip arthroplasty after proximal femoral osteotomy: 75 cases with 9-year follow-up].

Authors:  J C Delbarre; C Hulet; D Schiltz; J H Aubriot; C Vielpeau
Journal:  Rev Chir Orthop Reparatrice Appar Mot       Date:  2002-05

4.  Severe osteoarthritis of the hip and its surgical treatment by Pauwels' osteotomy.

Authors:  R Ueno
Journal:  Acta Orthop Belg       Date:  1978 Jan-Feb       Impact factor: 0.500

5.  Long-term results of valgus osteotomy for terminal-stage osteoarthritis of the hip.

Authors:  Suguru Ohsawa
Journal:  Arch Orthop Trauma Surg       Date:  2016-11-09       Impact factor: 3.067

6.  Long-term results of cementless femoral reconstruction following intertrochanteric osteotomy.

Authors:  Christian Merle; Marcus R Streit; Moritz Innmann; Tobias Gotterbarm; Peter R Aldinger
Journal:  Int Orthop       Date:  2012-01-12       Impact factor: 3.075

7.  What Is the Impact of a Previous Femoral Osteotomy on THA? A Systematic Review.

Authors:  Enrico Gallazzi; Ilaria Morelli; Giuseppe Peretti; Luigi Zagra
Journal:  Clin Orthop Relat Res       Date:  2019-05       Impact factor: 4.176

8.  Good survival of uncemented tapered stems for failed intertrochanteric osteotomy: a mean 16 year follow-up study in 45 patients.

Authors:  Dominik Parsch; Alexander W Jung; Marc Thomsen; Volker Ewerbeck; Peter R Aldinger
Journal:  Arch Orthop Trauma Surg       Date:  2007-09-18       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.